Enzeevu

Drug Overview

In the specialized field of Ophthalmology, the management of progressive retinal diseases has been transformed by the introduction of advanced medications. For patients facing the frightening prospect of central vision loss, preserving sight is our highest priority. Enzeevu is a highly effective medication utilized to combat abnormal blood vessel growth in the back of the eye.

Enzeevu is a powerful Biologic medication classified as a VEGF Inhibitor. It is an FDA-approved biosimilar to the well-known reference drug Eylea (aflibercept). A biosimilar is a highly similar, clinically equivalent version of an original biologic medicine, offering the same safety and effectiveness while increasing patient access to critical vision-saving treatments.

• Generic Name / Active Ingredient: aflibercept-abzv
• US Brand Names: Enzeevu
• Route of Administration: Intravitreal Injection (an injection directly into the vitreous jelly in the back of the eye)
• FDA Approval Status: Fully FDA-approved (August 2024)

What Is It and How Does It Work? (Mechanism of Action)

To understand how Enzeevu works, we must look at the physiological changes occurring in the retina. In conditions like Wet Age-Related Macular Degeneration (Wet AMD), the eye is starved of oxygen. In response, the body produces high levels of two specific proteins: Vascular Endothelial Growth Factor-A (VEGF-A) and Placental Growth Factor (PlGF).

These proteins act as signals, binding to natural receptors in the eye to trigger the creation of new blood vessels (neovascularization). Unfortunately, in the retina, these new vessels are highly fragile and abnormal. They leak blood and fluid into the macula (the center of the retina), causing swelling, structural damage, and rapid vision loss.

Enzeevu acts as an advanced Targeted Therapy. It is a recombinant fusion protein designed to act as a “decoy receptor.” When injected into the eye, Enzeevu molecules bind tightly to the excess VEGF-A and PlGF proteins before those proteins can reach the eye’s natural receptors. By trapping these signaling proteins, this VEGF Inhibitor effectively halts the command to grow new vessels. This molecular blockade stops active bleeding, dramatically reduces vascular permeability (leakage), and allows the swollen retina to dry out and heal.

FDA-Approved Clinical Indications

Enzeevu is carefully formulated for patients suffering from destructive vascular conditions of the retina.

• Primary Indication: Enzeevu is specifically approved as an aflibercept biosimilar for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (nAMD).
• Other Approved & Off-Label Uses: Due to its mechanism of action, it is also approved for:
  • Diabetic Macular Edema (DME)
  • Macular Edema following Retinal Vein Occlusion (RVO)
• Primary Ophthalmology Indications for Visual Preservation:
  • Stabilize the Blood-Retinal Barrier: By neutralizing VEGF, the drug stops abnormal fluid leakage, resolving macular edema and preventing the toxic accumulation of fluid inside the retinal layers.
  • Preserve Visual Acuity: By shrinking abnormal blood vessels and preventing scar tissue formation on the macula, this Biologic actively halts the progression of central blindness, allowing patients to maintain their ability to read, drive, and recognize faces.

Dosage and Administration Protocols

Proper administration is vital to ensure maximum efficacy and minimize the risk of severe intraocular infections. Because this is an intravitreal injection, the distinction between the “loading” and “maintenance” phases is critical.

Indication	Standard Dose	Frequency
Wet AMD (Loading Phase)	2 mg (0.05 mL)	Once every 4 weeks (approximately every 28 days) for the first 3 months (12 weeks)
Wet AMD (Maintenance Phase)	2 mg (0.05 mL)	Once every 8 weeks (2 months) following the loading phase
Macular Edema following RVO	2 mg (0.05 mL)	Once every 4 weeks (approximately every 28 days)
Diabetic Macular Edema (DME)	2 mg (0.05 mL)	Once every 4 weeks for the first 5 injections, then once every 8 weeks

Specific Instructions and Adjustments:

• Administration Technique: Injections must be performed under controlled, sterile conditions by a qualified physician. This includes the use of surgical hand sanitization, sterile gloves, a sterile drape, and a broad-spectrum microbicide (like povidone-iodine) applied to the ocular surface and eyelids prior to injection.
• Patient Populations: Safety and effectiveness in pediatric patients have not been established. No special dosage modifications are required for elderly patients.

Dosage must be individualized by a qualified healthcare professional.

Clinical Efficacy and Research Results

Current clinical study data (2020-2026) regarding aflibercept biosimilars emphasizes the concept of “totality of evidence.” In pivotal Phase 3 equivalence trials, aflibercept-abzv demonstrated equivalent clinical efficacy compared to the reference biologic.

In treating Wet AMD, clinical trial data shows that patients receiving this Targeted Therapy experience a highly comparable mean change in Best Corrected Visual Acuity (BCVA). By the end of a standard 48-week trial period, treated patients typically maintain or gain an average of 5 to 7 letters on the ETDRS vision chart. Furthermore, structural measurements via Optical Coherence Tomography (OCT) show an equivalent and significant reduction in Central Retinal Thickness (CRT), often decreasing by over 100 to 130 micrometers from baseline as the macular fluid resolves. This backup research data firmly establishes Enzeevu’s efficacy in aggressively preventing vision loss.

Safety Profile and Side Effects

Black Box Warning: There is NO Black Box Warning for Enzeevu. However, the intravitreal injection procedure inherently carries risks that must be managed.

Common Side Effects (>10%):

• Conjunctival hemorrhage (a harmless, temporary blood spot on the white of the eye)
• Eye pain or mild discomfort during or immediately after the injection
• Vitreous floaters (small moving spots in the field of vision)
• Cataract progression over extended, long-term use

Serious Adverse Events (Rare):

• Endophthalmitis (a severe, sight-threatening internal eye infection)
• Retinal detachment or retinal tear
• Intraocular inflammation (iritis or uveitis)
• Elevated Intraocular Pressure (IOP) immediately following the fluid injection
• A theoretical risk of systemic Arterial Thromboembolic Events (ATE), such as stroke or heart attack, following absorption into the bloodstream.

Management Strategies:

To mitigate infection risks, strict adherence to sterile administration techniques is non-negotiable. Following the injection, doctors must check the optic nerve perfusion to ensure the added fluid volume hasn’t caused a dangerous spike in eye pressure. Patients must be educated to immediately report sudden, severe pain, profound vision loss, or a sudden shower of new “floaters” to their clinic, as these are emergency signs of infection or retinal tearing.

Research Areas

As an approved biosimilar, Enzeevu itself represents a major research milestone in developing cost-effective, high-quality alternatives to standard Biologic therapies. However, the ophthalmic community is actively researching broader advancements to reduce the treatment burden on patients who currently require lifelong eye injections.

Generalization of current research highlights a massive shift toward advancements in Novel Delivery Systems. Scientists are heavily focused on sustained-release intraocular implants that can continuously deliver a VEGF Inhibitor over 6 to 9 months. Additionally, there is a strong pipeline developing Preservative-Free, higher-dose formulations to extend the time between required injections, as well as one-time gene therapy viral vectors for inherited and age-related retinal diseases that coax the eye into producing its own anti-VEGF medicine.

Disclaimer: The research described regarding Enzeevu and related ophthalmic advancements is currently exploratory and remains under ongoing investigation. These studies are not yet fully validated and are not applicable to routine clinical practice or professional treatment scenarios at this stage. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

Before initiating therapy, a rigorous baseline assessment is mandatory to map the disease’s severity and establish treatment goals.

• Baseline Diagnostics: Accurately record Baseline Visual Acuity. Perform Tonometry (IOP measurement) to establish baseline eye pressure, and conduct a detailed Slit-lamp exam to ensure there are no active eye infections.
• Ocular Imaging: High-resolution Optical Coherence Tomography (OCT) is strictly required to visualize fluid pockets, measure Central Retinal Thickness (CRT), and map the architecture of the macula. Fluorescein Angiography may be used initially to map out the exact location of the leaking blood vessels.
• Screening: Review the patient’s medical history for recent strokes, heart attacks, or a history of glaucoma.

Monitoring and Precautions

• Vigilance: Continuous monitoring via OCT at every appointment is required to determine if the macula is remaining “dry” or if the injection frequency needs to be adjusted. Physicians must monitor for sudden spikes in IOP immediately after the fluid is injected.
• Lifestyle: * Maintain a heart-healthy diet, as systemic vascular health directly impacts retinal vascular health. Consider dietary supplements like the AREDS2 formula if early-stage dry AMD is present in the fellow eye.
• “Do’s and Don’ts” list:
  • DO use sterile, artificial tear drops if your eye feels scratchy a few days after the injection (the iodine used to clean the eye can cause temporary dryness).
  • DO attend all scheduled injection appointments; missing doses allows the abnormal blood vessels to immediately start growing and bleeding again.
  • DON’T rub your eye for at least 3 days post-injection to prevent bacteria from entering the microscopic injection site.
  • DON’T swim or submerge your head in hot tubs for at least 3 days following the procedure.

Legal Disclaimer

The medical information provided in this guide is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your ophthalmologist, retina specialist, or other qualified healthcare provider regarding a medical condition. Standard clinical protocols and FDA approvals are subject to change; treatment must be individualized based on a comprehensive medical assessment. Never disregard professional medical advice or delay seeking it because of information provided herein.